Pharmacovigilance literature screening is the systematic monitoring of the published scientific and medical literature to identify articles that report adverse events, safety signals, and individual case safety reports for a medicinal product. Research Gold delivers this screening as a transparent, auditable review: a documented search strategy, dual-reviewer screening against pre-specified criteria, and a reproducible methods trail your safety team can stand behind in an inspection.
Why literature monitoring sits at the center of drug safety
Marketing authorization holders are expected to monitor the worldwide scientific and medical literature for safety information on their products, and to do it on a defined, repeatable schedule. The volume is the problem. Relevant safety information is scattered across thousands of new articles each week, most of which are irrelevant to any one product, and a single missed case report can carry regulatory and patient-safety consequences. Screening that flood efficiently, without letting a genuine report slip through, is a methodology problem before it is a safety problem, and it is precisely the kind of high-recall, dual-reviewer screening our team performs every day for published systematic reviews.
Our angle is deliberately narrow and honest. We provide the literature surveillance and screening step: building the search, running it on your cadence, and flagging the articles that contain potential case or signal information for your safety team to action. We do not process individual cases, author periodic safety update reports, submit expedited reports to regulators, or act as your qualified person, because those are regulated safety functions that require qualified pharmacovigilance staff and a validated safety database. Keeping the scope to screening is exactly what lets us do that step rigorously, transparently, and cost-effectively.
What a valid case in the literature looks like
An article is relevant to safety surveillance when it describes enough for a reportable event: an identifiable patient, an identifiable reporter, a suspect medicinal product, and an adverse event or reaction. The screening criteria we agree with you translate those minimum elements, plus your product-specific terms and any signal or special-situation categories you monitor, into an explicit, testable checklist. Two reviewers then apply that checklist to every record, which is the difference between a defensible screen and a subjective one. Ambiguous articles, such as reviews that mention an event without a discrete case, are flagged for your team rather than silently excluded.
